Sec Form 13G Filing - Nussbaum Ran @ LogicBio Therapeutics Inc.

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No. 1)

(Rule 13d-102)

Under the Securities Exchange Act of 1934

LogicBio Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

54142F102

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☐

Rule 13d-1(c)

☒

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 54142F102

13G

Page 2 of 10 Pages

Names of Reporting Persons

Ran Nussbaum

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(d) ☐

SEC Use Only

Citizenship or Place of Organization

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

Sole Voting Power

Shared Voting Power

1,629,053¹

Sole Dispositive Power

Shared Dispositive Power

1,629,053¹

Aggregate Amount Beneficially Owned by Each Reporting Person

1,629,053¹

10.

Ch eck if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

☐

11.

Percent of Class Represented by Amount in Row (9)

5.1%

12.

Type of Reporting Person (See Instructions)

Pontifax 4 G.P., Limited Partnership is the general partner of Pontifax (Israel) IV, Limited Partnership, Pontifax (Cayman) IV, L.P. and Pontifax (China) IV, L.P. Pontifax Management IV, G.P. (2015) Ltd. is the general partner of Pontifax 4 G.P., Limited Partnership. Ran Nussbaum and Tomer Kariv are directors of Pontifax IV, G.P. (2015) Ltd. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

CUSIP No. 54142F102

13G

Page 3 of 10 Pages

Names of Reporting Persons

Tomer Kariv

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(e) ☐

(f) ☐

SEC Use Only

Citizenship or Place of Organization

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

Sole Voting Power

8,033¹

Shared Voting Power

1,629,053²

Sole Dispositive Power

8,033¹

Shared Dispositive Power

1,629,053²

Aggregate Amount Beneficially Owned by Each Reporting Person

1,637,087³

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

☐

11.

Percent of Class Represented by Amount in Row (9)

5.2%

12.

Type of Reporting Person (See Instructions)

Consists of options to purchase 8,033 ordinary shares exercisable within 60 days of December 31, 2020.

See notes 1 and 2 above.

Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

CUSIP No. 54142F102

13G

Page 4 of 10 Pages

Names of Reporting Persons

Pontifax 4 G.P., Limited Partnership

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(g) ☐

(h) ☐

SEC Use Only

Citizenship or Place of Organization

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

Sole Voting Power

Shared Voting Power

1,629,053¹

Sole Dispositive Power

Shared Dispositive Power

1,629,053¹

Aggregate Amount Beneficially Owned by Each Reporting Person

1,629,053¹

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

☐

11.

Percent of Class Represented by Amount in Row (9)

5.1%

12.

Type of Reporting Person (See Instructions)

Consists of: (i) 803,673 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 392,457 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 432,923 shares of common stock owned by Pontifax (China) IV, L.P. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

CUSIP No. 54142F102

13G

Page 5 of 10 Pages

Names of Reporting Persons

Pontifax Management IV, G.P. (2015) Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(i) ☐

(j) ☐

SEC Use Only

Citizenship or Place of Organization

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

Sole Voting Power

Shared Voting Power

1,629,053¹

Sole Dispositive Power

Shared Dispositive Power

1,629,053¹

Aggregate Amount Beneficially Owned by Each Reporting Person

1,629,053¹

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

☐

11.

Percent of Class Represented by Amount in Row (9)

5.1%

12.

Type of Reporting Person (See Instructions)

CUSIP No. 54142F102

13G

Page 6 of 10 Pages

Introductory Note: This Schedule 13G is filed on behalf of Pontifax 4 G.P., Limited Partnership, a limited partnership organized under the laws of the State of Israel, Pontifax Management IV, G.P. (2015) Ltd., an Israeli company, Ran Nussbaum and Tomer Kariv (the “Reporting Persons”), in respect of shares of common stock of Lo gicBio Therapeutics, Inc.

Item 1(a).

Name of Issuer:

LogicBio Therapeutics, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:

65 Hayden Avenue, 2^nd Floor, Lexington, MA 02421

Item 2(a).

Name of Person Filing:

This Statement is filed on behalf of Pontifax 4 G.P., Limited Partnership, Pontifax Management IV, G.P. (2015) Ltd., Ran Nussbaum. and Tomer Kariv.

Item 2(b).

Address of Principal Offices or, if None, Residence:

The addresses of the Reporting Persons are:

Pontifax 4 G.P., Limited Partnership - 14 Shenkar St. Herzliya, 46140, Israel

Pontifax Management IV, G.P. (2015) Ltd. – 14 Shenkar St. Herzliya, 46140, Israel

Ran Nussbaum - 14 Shenkar St. Herzliya, 46140, Israel

Tomer Kariv - 14 Shenkar St. Herzliya, 46140, Israel

Item 2(c).

Citizenship:

Pontifax 4 G.P., Limited Partnership is organized in the State of Israel, Pontifax Management IV, G.P. (2015) Ltd. is incorporated in the State of Israel, Ran Nussbaum is a citizen of the State of Israel, and Tomer Kariv is a citizen of the State of Israel.

Item 2(d).

Title of Class of Securities:

Shares of common stock

Item 2(e).

CUSIP Number:

54142F102

CUSIP No. 54142F102

13G

Page 7 of 10 Pages

Item 3.

If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a:

Not applicable.

(a)

☐

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

☐

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

☐

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

☐

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

☐

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

☐

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

☐

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

☐

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

☐

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

(j)

☐

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

☐

Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4.

Ownership.

(a)

Amount beneficially owned:

Tomer Kariv: 1,637,087 shares¹

Other Reporting Persons: 1,629,053 shares

(b)

Percent of class:

5.2%¹

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or direct the vote:

Tomer Kariv – 8,033 shares

CUSIP No. 54142F102

13G

Page 8 of 10 Pages

(ii)

Shared power to vote or direct the vote: 1,629,053 shares¹

(iii)

Sole power to dispose or to direct the disposition of:

Tomer Kariv – 8,033 shares

(iv)

Shared power to dispose or to direct the disposition of: 1,629,053 shares¹

Includes: (i) 803,673 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 392,457 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 432,923 shares of common stock owned by Pontifax (China) IV, L.P. In addition, for Mr. Kariv, includes options to purchase 8,033 ordinary shares exercisable within 60 days of December 31, 2020.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

Not applicable.

CUSIP No. 54142F102

13G

Page 9 of 10 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

&# xA0;

Date: February 11, 2021

PONTIFAX 4 G.P., LIMITED PARTNERSHIP

By:	/s/ Pontifax Management IV G.P. (2015) Ltd.
Name:	Pontifax Management IV G.P. (2015) Ltd.
Title:	General Partner

By:	/s/ Ran Nussbaum
Name:	Ran Nussbaum
Title:	Director

PONTIFAX MANAGEMENT IV, G.P. (2015) LTD.

By:	/s/ Ran Nussbaum
Name:	Ran Nussbaum
Title:	Director

/s/ Tomer Kariv
TOMER KARIV

/s/ Ran Nussbaum
Ran Nussbaum

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

CUSIP No. 54142F102

13G

Page 10 of 10 Pages

EXHIBIT INDEX

Joint Filing Agreement, dated as of February 14, 2020, by and among Pontifax 4 G.P., Limited Partnership, Pontifax Management IV, G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv. (Incorporated by reference from the Schedule 13G filed by the Reporting Persons with respect to the Issuer on February 14, 2020).

Sec Form 13G Filing - Nussbaum Ran filing for LogicBio Therapeutics Inc. (LOGC) - 2021-02-11